Evidence map›Paper›PMID 42163549›Full record

ArticleCancer medicine2026

Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.

Osamu Maeda, Chie Tanaka, Kazuhiro Furukawa, Kazushi Miyata, Dai Shimizu, Shizuki Sugita, Koki Nakanishi, Takashi Hirose, Kazuyuki Mizuno, Fumie Kinoshita and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Osamu MaedaDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0003-4700-6541
Chie TanakaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuhiro FurukawaDepartment of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazushi MiyataDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Dai ShimizuDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shizuki SugitaDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Koki NakanishiDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi HiroseDepartment of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuyuki MizunoDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Fumie KinoshitaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Yachiyo KuwatsukaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Masahiko AndoDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Mitsuro KandaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroki KawashimaDepartment of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuichi AndoDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

Funding

Nagoya University Hospital
6 · The paper itself

Abstract

Zolbetuximab is an anti-claudin18.2 (CLDN18.2) antibody, and the addition of zolbetuximab in combination with fluoropyrimidine and oxaliplatin as a first-line treatment for CLDN18.2-positive and HER2-negative gastric or gastroesophageal junction adenocarcinoma has been shown to improve survival. However, the efficacy and safety of the combination of zolbetuximab with combinations other than fluoropyrimidine and oxaliplatin have not been elucidated. The objective of the present study is to evaluate the feasibility of combination treatment with trifluridine/tipiracil (FTD/TPI), which is effective as a third- or later-line treatment, and zolbetuximab. In this study, 32 patients with CLDN18.2-positive and HER2-negative unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma who received two or more lines of chemotherapy will be recruited. The patients will receive FTD/TPI (35 mg/m

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsTrifluridineAdultAgedAntibodies, MonoclonalDrug CombinationsErb-b2 Receptor Tyrosine KinasesFeasibility StudiesFemaleHumansMaleMiddle AgedAntibodies, MonoclonalDrug CombinationsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationzolbetuximabCLDN18.2gastric cancertrifluridine/tipiracilzolbetuximab

Identifiers

PMID42163549
PMCPMC13239157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.